September 21, 2005 -- Biogen Idec and Elan filed an FDA application to have tTysabri allowed back on the market, Novartis may sell its 42% stake in Chiron if Chiron does not allow Novartis to buy the rest of the company, Alnylam stopped work on its treatment for age-related macular degeneration, QLT said Visudyne failed a Phase III test in a sub-group of the same disease, the FDA extended for 3 months its deliberation on a alcohol dependence treatment from Cephalon and Alkermes, Alexion completed enrolling patients into a Phase III trial of its blood disorder treatment, OXiGENE will start a Phase II test of a vascular disrupting agent against ovarian cancer, Savient asked the FDA to keep all generic versions of oxandrolone off the market for 3 years, and in a landmark of sorts, the first drug to treat AIDS has lost patent protection. The Centient Biotech 200™ closed 34 points lower at 3842, a loss of .87%. More details...
